Comparison between the levels of Pentraxin-3 and soluble lectin like oxidized LDL receptor-1 in rheumatoid arthritis patients
DOI:
https://doi.org/10.61841/b3qw9f78Keywords:
sLOX-1, pentraxin-3, Rheumatoid arthritis, inflammatory biomarkers, Joint painAbstract
Rheumatoid arthritis can defined as autoimmune disease that characterized by inflammatory synovitis, joint pain and functional disability and this can lead to destruction in the articular cartilage and bone. Our objective is to assess serum level of sLOX-1 and PTX-3 in patient with rheumatoid arthritis (Study design: Case control study). Eighty four people were included in this study, all from AlYarmook Teaching Hospital during period from December 2019 to February 2020 Subjects were divided into three groups:1- Control group (non- patient group): involve 28 healthy subjects 2-Patient study group 1: involve 28 subjects suffering from mild sign of Rheumatoid arthritis.3- Patient study group 2: involve 28 subjects suffering from severe sign of Rheumatoid arthritis. All patients were diagnosed with Rheumatoid arthritis have tender, warm, swollen joints with joint stiffness usually in the morning or after period of inactivity with fatigue, fever and loss of appetite. Mild cases is tend to be affect the smaller joints like fingers , hand and toes of feet and severe cases the sign spread to wrist, knee, elbow, hips and shoulders.. Serum samples were analyzed by using (ELISA). There was significantly increasing in mean level of sLOX-1and PTX-3, it was significantly higher in severe RA patient group than mild RA patient group and healthy control group (P<0.001). We can conclude that we can use sLOX-1 and PTX-3 as diagnostic biomarkers of RA also it can be markers for severe RA disease.
Downloads
References
1-R. Khurana, S.M. BerneyClinical aspects of rheumatoid arthritis
Pathophysiology, 12 (2005), pp. 153-165
2-E. Kassem, R. Ghonimy, M. Adel, G. El-SharnobyNon traditional risk factors of carotid atherosclerosis in rheumatoid arthritis .Egypt Rheumatol, 33 (3) (2011), pp. 113-119
3-A.M. Alsalawy, A.I. Fathi, R.A. Kamel, I. EwisCorrelation between serum osteoprotegerin and atherosclerotic vascular disorders in rheumatoid arthritis patients.Egypt Rheumatol, 34 (1) (2012), pp. 35-42
4-Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861– 74.
5- Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094– 108.
6-Kume N, Kita T. Lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1) in atherogenesis. Trends Cardiovasc Med 2001; 11: 22– 5.
7- Nakagawa T, Akagi M, Hoshikawa H, Chen M, Yasuda T, Mukai S, et al. Lectin‐like oxidized low‐density lipoprotein receptor 1 mediates leukocyte infiltration and articular cartilage destruction in rat zymosan‐induced arthritis. Arthritis Rheum 2002; 46: 2486– 94.
8-Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T. Soluble lectin‐like oxidized LDL receptor‐1 (sLOX‐1) as a sensitive and specific biomarker for acute coronary syndrome: comparison with other biomarkers. J Cardiol 2010; 56: 159– 65.
9- Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, et al. Serum soluble lectinlike oxidized low‐density lipoprotein receptor‐1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 2005; 112: 812– 8.
10-A. Mantovani, C. Garlanda, A. Doni, B. BottazziPentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3.J Clin Immunol, 28 (2008), pp. 1-13
11-O.D. Ortega-Hernandez, N. Bassi, Y. Shoenfeld, J.M. AnayaThe long pentraxin 3 and its role in autoimmunity.Semin Arthritis Rheum, 39 (2009), pp. 38-54
12-P. Cieslik, A. HrycekLong pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications.Autoimmunity, 45 (2012), pp. 119-128
13-P. Cieslik, A. HrycekPentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus.Autoimmunity, 48 (2015), pp. 242-250
14-T. Deniz, M. Kizilgul, M. Uzunlulu, A. Oguz, B. IsbilenLevels of pentraxin 3 and relationship with disease activity in patients with ankylosing spondylitis.Acta Reumatol Port, 39 (2014), pp. 137-142
15-T.L. Skare, R. Nisihara, G.P. Ramos, S.R. Utiyama, I. Messias-ReasonPentraxin-3 levels in systemic lupus erythematosus: association with cumulative damage but not with disease activity.Joint Bone Spine, 82 (2015), pp. 466-467
16-A. Surdacki, J. Sulicka, M. Korkosz, T. Mikolajczyk, D. Telesinska-Jasiówka, E. Klimek, et al.Blood monocyte heterogeneity and markers of endothelial activation in ankylosing spondylitis.J Rheumatol, 41 (2014), pp. 481-489
17- Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T. Soluble lectin‐like oxidized LDL receptor‐1 (sLOX‐1) as a sensitive and specific biomarker for acute coronary syndrome: comparison with other biomarkers. J Cardiol 2010; 56: 159– 65.
18- Lubrano V, Del Turco S, Nicolini G, Di Cecco P, Basta G. Circulating levels of lectin‐like oxidized low‐density lipoprotein receptor‐1 are associated with inflammatory markers. Lipids 2008; 43: 945– 50.
19- Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anticitrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089– 93.
20- Keenan RT, Swearingen CJ, Yazici Y. Erythrocyte sedimentation rate and C‐reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol 2008; 26: 814– 9.
21- Nakagawa T, Yasuda T, Hoshikawa H, Shimizu M, Kakinuma T, Chen M, et al. LOX‐1 expressed in cultured rat chondrocytes mediates oxidized LDL‐induced cell death: possible role of dephosphorylation of Akt. Biochem Biophys Res Commun 2002; 299: 91– 7.
22- Tiwari RL, Singh V, Barthwal MK. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med Res Rev 2008; 28: 483– 544.
23- Chen M, Masaki T, Sawamura T. LOX‐1, the receptor for oxidized low‐density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002; 95: 89– 100.
24- I. Hollan, B. Bottazzi, I. Cuccovillo, Ø.T. Førre, K. Mikkelsen, K. Saatvedt, et al.Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease Arthritis Care Res (Hoboken), 62 (2010), pp. 378-385
25- E. Klimek, A. Skalska, B. Kwaśny-Krochin, A. Surdacki, J. Sulicka, M. Korkosz, et al.Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration Mediators Inflamm, 2014 (2014), pp. 1-12
26- F. Fazzini, G. Peri, A. Doni, G. Dell'Antonio, E. Dal Cin, E. Bozzolo, et al.PTX3 in smallvessel vasculitides: an independent indicator of disease activity produced at sites of inflammation Arthritis Rheum, 44 (2001), pp. 2841-2850
27-M.M. Mabrouk, M.A. Ghazy, T.M. HassanSerum pentraxin 3 and interleukin-6 are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis Egypt J Immunol, 17 (2010), pp. 87-99
28-A. Sharma, R. Khan, N. Gupta, A. Sharma, M.S. Zaheer, M. Abbas, et al.Acute phase reactant, Pentraxin 3, as a novel marker for the diagnosis of rheumatoid arthritis Clin Chim Acta, 480 (2018), pp. 65-70
29-S. Gittaboyina, R. Rani Koduganti, S. Datta Aedula, V.N. Reddy Panthula, S. Prasanna Jammula, R. Dasari, et al.Estimation of Pentraxin 3 and Porphyromonas gingivalis concentrations in patients with rheumatoid arthritis and periodontitis- an observational study J Clin Diagn Res, 11 (2017), pp. ZC09-ZC12
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
